User contributions for Muhammad Waleed

14:5114:51, 23 May 2024 diff hist +6,189‎ Glofitamab-gxbm ‎No edit summary current
14:4014:40, 23 May 2024 diff hist +2,614‎ N Glofitamab-gxbm ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=glofitamab. |aOrAn=a |drugClass=bispecific antibodies |indicationType=treatment |indication=COLUMVI (glofitamab) has been approved by the FDA for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or large B-cell lymphoma arising from follicular lymphoma aft..."
14:2214:22, 23 May 2024 diff hist +5,524‎ Rozanolixizumab-noli ‎No edit summary current
12:4312:43, 23 May 2024 diff hist +3,235‎ N Rozanolixizumab-noli ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Rozanolixizumab-noli (Rystiggo) |aOrAn=a |drugClass=Neonatal Fc receptor blocker |indicationType=treatment |indication=Rystiggo is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. |adverseReac..."

10:1510:15, 16 May 2024 diff hist +132‎ Avacincaptad pegol ‎No edit summary current
10:1410:14, 16 May 2024 diff hist +505‎ Talquetamab-tgvs ‎No edit summary current
10:1110:11, 16 May 2024 diff hist +3,255‎ N Avacincaptad pegol ‎ Created page with "{{DrugProjectFormSinglePage |genericName=Avacincaptad Pegol |drugClass=Avacincaptad pegol is a complement C5 protein inhibitor |indication=IZERVAY is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). |adverseReactions=Common adverse reactions (≥5% of patients) include conjunctival hemorrhage, increased intraocular pressure, and endophthalmitis. |blackBoxWarningTitle=There is no black box warning listed for IZERV..."
09:3109:31, 16 May 2024 diff hist +25‎ N File:Talvey (talquetamab-tgvs).png ‎ image for the drug Talvey current
09:2809:28, 16 May 2024 diff hist +1,807‎ Talquetamab-tgvs ‎No edit summary

20:3820:38, 13 May 2024 diff hist +2,766‎ N Talquetamab-tgvs ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Talquetamab-tgvs |aOrAn=a |drugClass=bispecific GPRC5D-directed CD3 T-cell engager |indicationType=treatment |indication=TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent..."

04:2204:22, 10 August 2023 diff hist +496‎ Triple M Syndrome ‎No edit summary Tag: Visual edit
04:1904:19, 10 August 2023 diff hist +314‎ Triple M Syndrome ‎ →‎Historical Perspective Tag: Visual edit
04:0504:05, 10 August 2023 diff hist +246‎ m Triple M Syndrome ‎No edit summary Tag: Visual edit: Switched
03:5403:54, 10 August 2023 diff hist +5,250‎ N Triple M Syndrome ‎ Created page with "__NOTOC__ {{SI}} '''For patient information, click Insert page name here''' {{CMG}} {{SK}} == Overview == ==Historical Perspective== ==Classification== == Pathophysiology== === Genetics === === Associated Conditions=== ===Gross Pathology=== ===Microscopic Pathology=== ==Causes== ===Life Threatening Causes=== Life-threatening causes include conditions which may result in death or permanent disability within 24 ho..."
03:2903:29, 10 August 2023 diff hist +84‎ N Template:MWA ‎ Created page with "Muhammad Waleed, M.B.B.S.[mailto:muhammad_waleed@ymail.com]" current